Abstract
The deep lungs provide an efficient pathway for drugs to transport into the systemic circulation, as the extremely large surface area and thin epithelial membrane enable rapid drug transport to the blood stream. To penetrate into the deep lungs, aerosol particles with aerodynamic diameters of 1-3 m are optimal. Large porous hollow particles (LPHPs) can achieve this aerodynamic size range through enhanced porosity within the particles (typically < 0.4 g/cm3), which aerodynamically balances the large particle size (> 5 µm, up to 30 µm). The physical properties of these particles provide some key advantages compared to their small, nonporous counterparts through enhanced dispersibility, efficient deep lung deposition, and avoidance of phagocytic clearance. This review highlights the potential of LPHPs in pulmonary delivery of systemic drugs, with a focus on their critical attributes and key formulation aspects. In addition, three examples of LPHPs under development are presented to emphasize the potential of this technology to treat systemic diseases.
Keywords: PulmoSpheres, nanoparticle aggregates, porosity, dispersibility, aerodynamic diameter, systemic circulation.
Current Pharmaceutical Design
Title:Large Porous Hollow Particles: Lightweight Champions of Pulmonary Drug Delivery
Volume: 22 Issue: 17
Author(s): Sachin Gharse and Jennifer Fiegel
Affiliation:
Keywords: PulmoSpheres, nanoparticle aggregates, porosity, dispersibility, aerodynamic diameter, systemic circulation.
Abstract: The deep lungs provide an efficient pathway for drugs to transport into the systemic circulation, as the extremely large surface area and thin epithelial membrane enable rapid drug transport to the blood stream. To penetrate into the deep lungs, aerosol particles with aerodynamic diameters of 1-3 m are optimal. Large porous hollow particles (LPHPs) can achieve this aerodynamic size range through enhanced porosity within the particles (typically < 0.4 g/cm3), which aerodynamically balances the large particle size (> 5 µm, up to 30 µm). The physical properties of these particles provide some key advantages compared to their small, nonporous counterparts through enhanced dispersibility, efficient deep lung deposition, and avoidance of phagocytic clearance. This review highlights the potential of LPHPs in pulmonary delivery of systemic drugs, with a focus on their critical attributes and key formulation aspects. In addition, three examples of LPHPs under development are presented to emphasize the potential of this technology to treat systemic diseases.
Export Options
About this article
Cite this article as:
Gharse Sachin and Fiegel Jennifer, Large Porous Hollow Particles: Lightweight Champions of Pulmonary Drug Delivery, Current Pharmaceutical Design 2016; 22 (17) . https://dx.doi.org/10.2174/1381612822666160128145356
DOI https://dx.doi.org/10.2174/1381612822666160128145356 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Basis of Familial and Sporadic Alzheimer's Disease
Current Alzheimer Research The Anti-Inflammatory Potential of ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Evidence from Basic and Clinical Research
Current Drug Targets Biological Therapies in Osteoarthritis
Current Pharmaceutical Design Sulfonyl Group-Containing Compounds in the Design of Potential Drugs for the Treatment of Diabetes and Its Complications
Current Medicinal Chemistry Developing Histone Deacetylase Inhibitors as Anti-Cancer Therapeutics
Current Medicinal Chemistry Interception of Cocaine by Enzyme or Antibody Delivered with Viral Gene Transfer: A Novel Strategy for Preventing Relapse in Recovering Drug Users
CNS & Neurological Disorders - Drug Targets Diabetes and Chronic Heart Failure: From Diabetic Cardiomyopathy to Therapeutic Approach
Endocrine, Metabolic & Immune Disorders - Drug Targets Preventing Type 2 Diabetes Mellitus: Room for Residual Risk Reduction After Lifestyle Changes?
Current Pharmaceutical Design Are we Genomic Mosaics? Variations of the Genome of Somatic Cells can Contribute to Diversify our Phenotypes
Current Genomics Does RSV Infection Alter the Course of Chronic Lung Disease in Prematurely Born Infants?
Current Respiratory Medicine Reviews Subclassification and Nomenclature of α- and β-Adrenoceptors
Current Topics in Medicinal Chemistry Neurophysiological Mechanisms Related to Pain Management in Bone Tumors
Current Neuropharmacology Ephedrines and their Acyclic Derivatives
Current Organic Synthesis Cardioprotection by Regular Ethanol Consumption: Potential Mechanisms and Clinical Application
Current Drug Abuse Reviews Treatment Resistant OCD: Conceptualization and Treatment
Current Psychiatry Reviews Protein-Based HIV-1 Microbicides
Current HIV Research Review of Evidence-Based Psychotherapies for Pediatric Mood and Anxiety Disorders
Current Psychiatry Reviews Stem Cell Ageing and Apoptosis
Current Pharmaceutical Design Association of Lipoprotein-associated Phospholipase A2 Activity with Components of the Metabolic Syndrome in Apparently Healthy Boys
Cardiovascular & Hematological Agents in Medicinal Chemistry Cardiovascular Proteomics
Current Proteomics